AI Article Synopsis

  • Pneumococcus remains a significant health issue, causing around 100,000 hospitalizations and 30,000 invasive disease cases annually among U.S. adults, despite effective vaccines being available.
  • Previous surveys revealed that healthcare providers have limited knowledge about pneumococcal vaccine recommendations, leading to low vaccination coverage.
  • A recent survey of 751 providers indicated a majority supportive of expanding recommendations for the new 20-valent vaccine (PCV20) and highlighted the need for improved awareness and resources like the PneumoRecs VaxAdvisor app to facilitate better patient vaccination guidance.

Article Abstract

Despite the availability of effective vaccines against pneumococcal disease, pneumococcus is a common bacterial cause of pneumonia, causing approximately 100,000 hospitalizations among U.S. adults per year. In addition, approximately 30,000 invasive pneumococcal disease (IPD) cases and 3,000 IPD deaths occur among U.S. adults each year. Previous health care provider surveys identified gaps in provider knowledge about and understanding of the adult pneumococcal vaccine recommendations, and pneumococcal vaccine coverage remains suboptimal. To assess the feasibility and acceptability domains of the Advisory Committee on Immunization Practices (ACIP) Evidence to Recommendations (EtR) framework, a health care provider knowledge and attitudes survey was conducted during September 28-October 10, 2022, by the Healthcare and Public Perceptions of Immunizations Survey Collaborative before the October 2022 ACIP meeting. Among 751 provider respondents, two thirds agreed or strongly agreed with the policy option under consideration to expand the recommendations for the new 20-valent pneumococcal conjugate vaccine (PCV20) to adults who had only received the previously recommended 13-valent pneumococcal conjugate vaccine (PCV13). Gaps in providers' knowledge and perceived challenges to implementing recommendations were identified and were included in ACIP's EtR framework discussions in late October 2022 when ACIP updated the recommendations for PCV20 use in adults. Currently, use of PCV20 is recommended for certain adults who have previously received PCV13, in addition to those who have never received a pneumococcal conjugate vaccine. The survey findings indicate a need to increase provider awareness and implementation of pneumococcal vaccination recommendations and to provide tools to assist with patient-specific vaccination guidance. Resources available to address the challenges to implementing pneumococcal vaccination recommendations include the PneumoRecs VaxAdvisor mobile app and other CDC-developed tools, including summary documents and overviews of vaccination schedules and CDC's strategic framework to increase confidence in vaccines and reduce vaccine-preventable diseases, Vaccinate with Confidence.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495187PMC
http://dx.doi.org/10.15585/mmwr.mm7236a2DOI Listing

Publication Analysis

Top Keywords

pneumococcal conjugate
16
conjugate vaccine
16
health care
12
care provider
12
provider knowledge
12
pneumococcal
10
knowledge attitudes
8
adult pneumococcal
8
recommendations
8
vaccine recommendations
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!